NeoGenomics (NASDAQ:NEO – Get Free Report) and GRI Bio (NASDAQ:GRI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Earnings & Valuation
This table compares NeoGenomics and GRI Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeoGenomics | $727.33 million | 1.29 | -$108.03 million | ($0.84) | -8.57 |
| GRI Bio | N/A | N/A | -$11.96 million | ($235.02) | -0.01 |
Risk and Volatility
NeoGenomics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.38, meaning that its share price is 238% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for NeoGenomics and GRI Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeoGenomics | 1 | 8 | 5 | 0 | 2.29 |
| GRI Bio | 1 | 0 | 2 | 0 | 2.33 |
NeoGenomics currently has a consensus target price of $11.86, suggesting a potential upside of 64.68%. GRI Bio has a consensus target price of $644.00, suggesting a potential upside of 28,395.58%. Given GRI Bio’s stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than NeoGenomics.
Institutional & Insider Ownership
98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 2.4% of NeoGenomics shares are held by insiders. Comparatively, 8.7% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares NeoGenomics and GRI Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeoGenomics | -14.85% | -3.10% | -1.85% |
| GRI Bio | N/A | -381.74% | -206.45% |
Summary
NeoGenomics beats GRI Bio on 7 of the 13 factors compared between the two stocks.
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
